Read by QxMD icon Read

Stephen Cady

Philip J O'Connell, Weijia Zhang, Madhav C Menon, Zhengzi Yi, Bernd Schröppel, Lorenzo Gallon, Yi Luan, Ivy A Rosales, Yongchao Ge, Bojan Losic, Caixia Xi, Christopher Woytovich, Karen L Keung, Chengguo Wei, Ilana Greene, Jessica Overbey, Emilia Bagiella, Nader Najafian, Milagros Samaniego, Arjang Djamali, Stephen I Alexander, Brian J Nankivell, Jeremy R Chapman, Rex Neal Smith, Robert Colvin, Barbara Murphy
BACKGROUND: Chronic injury in kidney transplants remains a major cause of allograft loss. The aim of this study was to identify a gene set capable of predicting renal allografts at risk of progressive injury due to fibrosis. METHODS: This Genomics of Chronic Allograft Rejection (GoCAR) study is a prospective, multicentre study. We prospectively collected biopsies from renal allograft recipients (n=204) with stable renal function 3 months after transplantation. We used microarray analysis to investigate gene expression in 159 of these tissue samples...
September 3, 2016: Lancet
Stephen D Silberstein, Anne H Calhoun, Richard B Lipton, Brian M Grosberg, Roger K Cady, Stefanie Dorlas, Kristy A Simmons, Chris Mullin, Eric J Liebler, Peter J Goadsby, Joel R Saper
OBJECTIVE: To evaluate the feasibility, safety, and tolerability of noninvasive vagus nerve stimulation (nVNS) for the prevention of chronic migraine (CM) attacks. METHODS: In this first prospective, multicenter, double-blind, sham-controlled pilot study of nVNS in CM prophylaxis, adults with CM (≥15 headache d/mo) entered the baseline phase (1 month) and were subsequently randomized to nVNS or sham treatment (2 months) before receiving open-label nVNS treatment (6 months)...
August 2, 2016: Neurology
Hong Sun, David W Dodick, Stephen Silberstein, Peter J Goadsby, Uwe Reuter, Messoud Ashina, Joel Saper, Roger Cady, Yun Chon, Julie Dietrich, Robert Lenz
BACKGROUND: The calcitonin gene-related peptide (CGRP) pathway is a promising target for preventive therapies in patients with migraine. We assessed the safety and efficacy of AMG 334, a fully human monoclonal antibody against the CGRP receptor, for migraine prevention. METHODS: In this multicentre, randomised, double-blind, placebo-controlled, phase 2 trial, patients aged 18-60 years with 4 to 14 migraine days per month were enrolled at 59 headache and clinical research centres in North America and Europe, and randomly assigned in a 3:2:2:2 ratio to monthly subcutaneous placebo, AMG 334 7 mg, AMG 334 21 mg, or AMG 334 70 mg using a sponsor-generated randomisation sequence centrally executed by an interactive voice response or interactive web response system...
April 2016: Lancet Neurology
Stephen H Kasper, Richard P Bonocora, Joseph T Wade, Rabi Ann Musah, Nathaniel C Cady
The opportunistic pathogen Pseudomonas aeruginosa utilizes multiple quorum sensing (QS) pathways to coordinate an arsenal of virulence factors. We previously identified several cysteine-based compounds inspired by natural products from the plant Petiveria alliacea which are capable of antagonizing multiple QS circuits as well as reducing P. aeruginosa biofilm formation. To understand the global effects of such compounds on virulence factor production and elucidate their mechanism of action, RNA-seq transcriptomic analysis was performed on P...
April 15, 2016: ACS Chemical Biology
M Craven, S H Kasper, M J Canfield, R R Diaz-Morales, J A Hrabie, N C Cady, A D Strickland
AIMS: To test the antimicrobial and antibiofilm properties of a nitric oxide (NO)-releasing polymer against wound-relevant bacterial pathogens. METHODS AND RESULTS: Using a variety of 96-well plate assay systems that include standard well plates and the minimum biofilm eradication concentration biofilm assay well plate, a NO-releasing polymer based on (poly)acrylonitrile (PAN/NO) was studied for antimicrobial and antibiofilm activity against the common wound pathogens Pseudomonas aeruginosa (PAO1), Staphylococcus aureus (Mu50) and Enterococcus faecalis (V583)...
April 2016: Journal of Applied Microbiology
Stewart J Tepper, Roger K Cady, Stephen Silberstein, John Messina, Ramy A Mahmoud, Per G Djupesland, Paul Shin, Joao Siffert
OBJECTIVE: The objective of this study was to compare the efficacy, tolerability, and safety of AVP-825, an investigational bi-directional breath-powered intranasal delivery system containing low-dose (22 mg) sumatriptan powder, vs 100 mg oral sumatriptan for acute treatment of migraine in a double-dummy, randomized comparative efficacy clinical trial allowing treatment across multiple migraine attacks. BACKGROUND: In phases 2 and 3, randomized, placebo-controlled trials, AVP-825 provided early and sustained relief of moderate or severe migraine headache in adults, with a low incidence of triptan-related adverse effects...
May 2015: Headache
Stephen H Landy, Roger K Cady, Andrew Nelsen, Jonathan White, M Chris Runken
OBJECTIVES: To assess the consistency of improved functioning, productivity, and medication satisfaction in migraines treated with a single tablet of sumatriptan 85 mg/naproxen sodium 500 mg (S/NS) using an early intervention approach. METHODS: Two randomized, double-blind, placebo-controlled, 4-period crossover, multi-attack, multi-center, outpatient studies of moderate to severe adult migraineurs were conducted to compare S/NS with placebo. Participants recorded outcome assessments in a diary during the 24 hours following study medication...
April 2014: Headache
Stephen D Silberstein, Andrew M Blumenfeld, Roger K Cady, Ira M Turner, Richard B Lipton, Hans-Christoph Diener, Sheena K Aurora, Mai Sirimanne, Ronald E DeGryse, Catherine C Turkel, David W Dodick
Acute headache medication overuse (MO) is common in patients with chronic migraine (CM). We evaluated safety and efficacy of onabotulinumtoxinA as preventive treatment of headache in CM patients with baseline MO (CM+MO) in a planned secondary analysis from two similarly designed, randomized, placebo-controlled, parallel, Phase III trials. Patients were randomized to treatment groups (155-195 U of onabotulinumtoxinA or placebo) using MO (patient-reported and diary-captured frequency of intake) as a stratifying variable...
August 15, 2013: Journal of the Neurological Sciences
Nathaniel C Cady, Kurt A McKean, Jason Behnke, Roman Kubec, Aaron P Mosier, Stephen H Kasper, David S Burz, Rabi A Musah
Using a microplate-based screening assay, the effects on Pseudomonas aeruginosa PAO1 biofilm formation of several S-substituted cysteine sulfoxides and their corresponding disulfide derivatives were evaluated. From our library of compounds, S-phenyl-L-cysteine sulfoxide and its breakdown product, diphenyl disulfide, significantly reduced the amount of biofilm formation by P. aeruginosa at levels equivalent to the active concentration of 4-nitropyridine-N-oxide (NPO) (1 mM). Unlike NPO, which is an established inhibitor of bacterial biofilms, our active compounds did not reduce planktonic cell growth and only affected biofilm formation...
2012: PloS One
Frederick Derosier, Fred Sheftell, Stephen Silberstein, Roger Cady, Gary Ruoff, Alok Krishen, Margaret Peykamian
OBJECTIVES: The primary objective was to compare the efficacy of a sumatriptan and naproxen combination medication (SumaRT/Nap-85mg sumatriptan and 500mg naproxen sodium), a butalbital-containing combination medication (BCM-50mg butalbital, 325mg acetaminophen, 40mg caffeine), and placebo when used to treat moderate to severe migraine headache pain in subjects who used BCMs in the past. BACKGROUND: Despite the lack of Food and Drug Administration approval and the absence of placebo-controlled trials to demonstrate efficacy, butalbital-containing medications are among the most commonly prescribed acute migraine treatments in the United States...
April 2012: Headache
John F Rothrock, Roger K Cady, Sheena K Aurora, Jan Lewis Brandes, Judith A Myers, Anthony W Fox, Stephen J Farr
OBJECTIVE: To evaluate efficacy of, satisfaction with, and confidence in SDP (SUMAVEL DosePro *) among triptan users requiring a change in therapy. SDP is a needle-free, subcutaneous sumatriptan product that confers relief as early as 10 minutes postdose. RESEARCH DESIGN AND METHODS: In an open-label study, SDP was administered for ≤4 migraine attacks over ≤60 days by migraineurs currently treated with triptans (any form/dosage). In the 90 patients with baseline Migraine-ACT scores ≤2 (indicating the need for a change in therapy), efficacy data were collected from patient diaries, and satisfaction was measured with the revised Patient Perception of Migraine Questionnaire (PPMQ-R)...
November 2011: Current Medical Research and Opinion
Roger K Cady, Sheena K Aurora, Jan L Brandes, John F Rothrock, Judith A Myers, Anthony W Fox, Stephen J Farr
OBJECTIVE: To evaluate patient satisfaction with and confidence in Sumavel® DosePro® (needle-free subcutaneous sumatriptan) among current triptan users administering Sumavel DosePro for up to 4 migraine attacks. BACKGROUND: Sumavel DosePro is a needle-free, single-use device that facilitates subcutaneous injection of sumatriptan 6 mg and confers relief as early as 10 minutes after dosing. DESIGN/METHODS: In this open-label, multicenter study, Sumavel DosePro was self-administered for ≤4 migraine attacks (over a ≤60-day period) involving moderate or severe baseline pain by adult migraineurs who currently were using triptans (any form, any dosage) and reported being less than very satisfied with their current therapy (i...
September 2011: Headache
Roger Cady, Jim Banks, Robert B Nett, Jerome Goldstein, Nathan Bennett, Ira M Turner, Gary E Ruoff, Stephen H Landy, Kathleen Farmer, Márta Juhász, Jeanne Tarrasch, M Chris Runken
OBJECTIVE: To investigate a broad definition of migraine resolution that extends beyond specific migraine-associated diagnostic symptoms as measured by the Completeness of Response Survey. METHODS: Conducted at 8 sites, 135 subjects treated migraines with SumaRT/Nap over 2 months. To measure subjects' experiences with SumaRT/Nap compared to their usual migraine medication, the Headache Impact Test, Revised Patient Perception of Migraine Questionnaire, and Completeness of Response Survey were administered at baseline and at 2 months...
June 2011: Headache
Richard B Lipton, Stephen Silberstein, David Dodick, Roger Cady, Fred Freitag, Ninan Mathew, David M Biondi, Steven Ascher, William H Olson, Joseph Hulihan
OBJECTIVE: The study sought to evaluate whether topiramate prevents development of chronic daily headache (CDH, ≥15 headache days per month) in adult subjects with high-frequency episodic migraine (HFEM, 9-14 migraine headache days/month). A secondary objective was to assess the efficacy of topiramate as preventive migraine treatment in this population. METHODS: This was a multicenter, randomized, double-blind, placebo-controlled study comparing topiramate 100 mg/day and placebo for 26 weeks...
January 2011: Cephalalgia: An International Journal of Headache
Jan Lewis Brandes, Roger K Cady, Fred G Freitag, Timothy R Smith, Patricia Chandler, Anthony W Fox, Lawrence Linn, Stephen J Farr
BACKGROUND: Subcutaneous (s.c.) injection of sumatriptan is currently associated with needle aversion in some patients, and sharps disposal issues. OBJECTIVES: To investigate whether a needle-free system can deliver s.c. sumatriptan. If so, to examine whether needle-free administration is bioequivalent to a 26-gauge needle-based auto-injector. Lastly, to assess the needle-free system for clinical acceptability and ease of use during migraine attacks. METHODS: Two clinical trials...
November 2009: Headache
Roger K Cady, Jerome Goldstein, Stephen Silberstein, Márta Juhász, Karen Ramsey, Anthony Rodgers, Carolyn M Hustad, Tony Ho
OBJECTIVE: To evaluate whether access to more liberal quantities of rizatriptan improves clinical outcome in patients with episodic migraine. BACKGROUND: Currently many pharmacy benefit programs limit the number of triptan tablets/injections per month based on perceived cost savings and the belief that too-frequent use of triptans may lead to medication overuse headache and headache chronification. METHODS: This observer-blind, randomized, parallel-group study enrolled 197 subjects with migraine with or without aura...
November 2009: Headache
Gordon F Schwartz, Kevin S Hughes, Henry T Lynch, Carol J Fabian, Ian S Fentiman, Mark E Robson, Susan M Domchek, Lynn C Hartmann, Roland Holland, David J Winchester, Benjamin O Anderson, Banu K Arun, Harry Bartelink, Philip Bernard, Bernardo Bonanni, Blake Cady, Krishna B Clough, Stephen A Feig, Sylvia H Heywang-Köbrunner, Anthony Howell, Claudine Isaacs, Daniel B Kopans, Robert E Mansel, Shahla Masood, Juan P Palazzo, Peter I Pressman, Lawrence J Solin, Michael Untch
A consensus conference including thirty experts was held in April, 2007, to discuss risk factors for breast cancer and their management. Four categories of risk were outlined, from breast cancer "average" through "very high" risk, the latter including individuals with high penetrance BRCA1/2 gene mutations. Guidelines for management of patients in each of these categories were discussed, with the major portion of the conference being devoted to individuals with BRCA1/2 mutations. Prevalence of these mutations in the general populations was estimated to be 1 in 250-500 individuals, with an increased prevalence in Ashkenazic Jews and other founder groups...
January 2009: Breast Journal
David W Dodick, Stephen Silberstein, Joel Saper, Fred G Freitag, Roger K Cady, Alan M Rapoport, Ninan T Mathew, Joseph Hulihan, Concetta Crivera, Marcia F T Rupnow, Lian Mao, Gary Finlayson, Steven J Greenberg
BACKGROUND: Chronic migraine is a disabling primary chronic daily headache disorder that significantly impacts the daily activities of patients with this disorder. To our knowledge, this is the first report of a large, randomized, double-blind, placebo-controlled trial that assessed the impact of topiramate on the daily activities, emotional distress, headache-related disability, and global impression of change in patients with chronic migraine. OBJECTIVE: To assess whether topiramate 100 mg/day reduces migraine-related disability and limitations of daily activities in patients with chronic migraine...
November 2007: Headache
Stephen D Silberstein, Roger K Cady, Fred D Sheftell, Mary Almas, Bruce Parsons, Kenneth S Albert
OBJECTIVE: To provide a multidimensional assessment of the extent of functional impairment during an acute migraine attack, and of the improvement in functioning in response to treatment, using 4 concurrently administered scales: the 7-item work productivity questionnaire (PQ-7), the functional assessment in migraine (FAIM) activities and participation (FAIM-A&P) subscale, the FAIM-impact of migraine on mental functioning (FAIM-IMMF) subscale, and the traditional 4-point global functional impairment scale (FIS)...
May 2007: Headache
Ning Gao, N Gabriel Armatas, James B Shanley, Neil C Kamman, Eric K Miller, Gerald J Keeler, Timothy Scherbatskoy, Thomas M Holsen, Thomas Young, Lyn McIlroy, Stephen Drake, Bill Olsen, Carol Cady
A mass balance model for mercury in Lake Champlain was developed in an effort to understand the sources, inventories, concentrations, and effects of mercury (Hg) contamination in the lake ecosystem. To construct the mass balance model, air, water, and sediment were sampled as a part of this project and other research/monitoring projects in the Lake Champlain Basin. This project produced a STELLA-based computer model and quantitative apportionments of the principal input and output pathways of Hg for each of 13 segments in the lake...
January 1, 2006: Environmental Science & Technology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"